Merrimack Pharmaceuticals (MACK) Files $172.5M IPO
Tweet
Share
E-mailGet Alerts MACK Hot Sheet
Join SI Premium – FREE
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount is $172.5 million. Merrimack plans to list on the Nasdaq Global Market under the ticker "MACK."
The offering is being made through J.P. Morgan, BofA Merrill Lynch, Cowen and Company, and Oppenheimer & Co.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
The offering is being made through J.P. Morgan, BofA Merrill Lynch, Cowen and Company, and Oppenheimer & Co.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
